Neurocrine Biosciences, Inc. (NBIX) Insider Sells $104,039.00 in Stock
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Haig P. Bozigian sold 1,300 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $80.03, for a total value of $104,039.00. Following the transaction, the insider now owns 143,276 shares of the company’s stock, valued at approximately $11,466,378.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Haig P. Bozigian also recently made the following trade(s):
- On Monday, May 13th, Haig P. Bozigian sold 34,547 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $75.51, for a total value of $2,608,643.97.
Shares of NBIX traded down $1.04 during trading hours on Thursday, reaching $78.75. 547,800 shares of the company traded hands, compared to its average volume of 947,659. The firm has a market capitalization of $7.28 billion, a price-to-earnings ratio of 357.95 and a beta of 1.73. The company has a current ratio of 8.79, a quick ratio of 8.61 and a debt-to-equity ratio of 0.96. Neurocrine Biosciences, Inc. has a 12 month low of $64.72 and a 12 month high of $126.98.
Institutional investors and hedge funds have recently made changes to their positions in the company. Norges Bank purchased a new position in Neurocrine Biosciences during the 4th quarter valued at about $61,171,000. Orbimed Advisors LLC lifted its position in Neurocrine Biosciences by 258.6% during the 4th quarter. Orbimed Advisors LLC now owns 494,200 shares of the company’s stock valued at $35,291,000 after acquiring an additional 356,400 shares during the period. Thrivent Financial for Lutherans lifted its position in Neurocrine Biosciences by 94.5% during the 4th quarter. Thrivent Financial for Lutherans now owns 691,851 shares of the company’s stock valued at $49,405,000 after acquiring an additional 336,101 shares during the period. First Trust Advisors LP lifted its position in Neurocrine Biosciences by 27.3% during the 4th quarter. First Trust Advisors LP now owns 1,299,455 shares of the company’s stock valued at $92,794,000 after acquiring an additional 278,598 shares during the period. Finally, Marshall Wace North America L.P. lifted its position in Neurocrine Biosciences by 83.5% during the 1st quarter. Marshall Wace North America L.P. now owns 580,904 shares of the company’s stock valued at $51,178,000 after acquiring an additional 264,402 shares during the period.
Several equities research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating and set a $105.00 price objective for the company in a research report on Wednesday, April 10th. BidaskClub upgraded shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, May 4th. Credit Suisse Group started coverage on shares of Neurocrine Biosciences in a report on Monday. They issued an “outperform” rating and a $95.00 target price on the stock. Barclays restated a “buy” rating and issued a $110.00 target price on shares of Neurocrine Biosciences in a report on Friday, March 29th. Finally, Evercore ISI initiated coverage on shares of Neurocrine Biosciences in a research report on Thursday, April 11th. They issued an “outperform” rating for the company. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $102.95.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Read More: Beige Book
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.